Last updated: October 9, 2026
Indocin is the branded form of indomethacin, a nonsteroidal anti-inflammatory drug sold primarily for acute gout, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, bursitis, tendinitis, and other inflammatory conditions. Its commercial profile is mature and largely genericized. The brand has limited pricing power, no meaningful new-drug exclusivity, and no publicly disclosed standalone revenue stream. Its remaining value is concentrated in brand recognition, niche dosage forms, distribution, and physician familiarity.
What is the current market position of Indocin?
Indocin competes in a large but highly commoditized NSAID market. Generic indomethacin is available in capsules, extended-release capsules, suppositories, and oral suspension, depending on jurisdiction and product availability. The main commercial products are:
| Product |
Active ingredient |
Primary role |
Market position |
| Indocin capsules |
Indomethacin |
Acute and chronic inflammatory disorders |
Mature branded product with generic substitution |
| Indocin suppositories |
Indomethacin |
Patients unable to take oral medication |
Niche dosage form |
| Indocin oral suspension |
Indomethacin |
Pediatric or swallowing-limited use |
Small specialty segment |
| Generic indomethacin |
Indomethacin |
Same approved indications |
Price-led market |
| Tivorbex |
Indomethacin |
Acute treatment of mild-to-moderate pain |
Branded reformulation with differentiated dosing |
| Indomethacin injection products |
Indomethacin sodium trihydrate |
Neonatal patent ductus arteriosus closure |
Separate hospital market |
Indocin is no longer positioned as a premium innovation product. Its commercial performance depends on prescriptions that remain brand-specific, supply reliability, dosage-form availability, and contracting rather than clinical differentiation.
The label carries standard NSAID risks, including gastrointestinal bleeding, cardiovascular thrombotic events, renal toxicity, and serious hypersensitivity reactions. These risks constrain chronic use and support competition from drugs perceived as easier to tolerate, including naproxen, ibuprofen, celecoxib, and topical NSAIDs. [1]
How has Indocin’s financial trajectory developed?
Indocin’s financial trajectory follows the standard life cycle of an older small-molecule product:
- Patent-protected originator growth.
- Generic entry and rapid price erosion.
- Brand retention in selected prescriptions and dosage forms.
- Long-tail revenue from limited competition, supply gaps, and institutional purchasing.
- Declining or flat nominal sales without a new formulation or commercial repositioning.
Public filings do not generally report Indocin revenue separately. Product-level financial data are therefore not available from the manufacturer’s consolidated disclosures. The absence of standalone revenue reporting indicates that Indocin is not a material disclosed revenue driver for a diversified pharmaceutical company.
Revenue exposure and margin profile
The economic profile is likely divided between:
- Low-margin generic indomethacin supplied by multiple manufacturers.
- Higher-margin branded Indocin prescriptions that avoid automatic substitution.
- Niche revenue from suppositories and oral suspension.
- Contract or institutional sales where product availability has greater value than brand equity.
Brand revenue is exposed to three structural pressures:
| Pressure |
Financial effect |
| Generic substitution |
Reduces branded prescription volume and net price |
| Multiple approved manufacturers |
Limits supply-based pricing power |
| NSAID safety concerns |
Restricts chronic-use demand and favors alternatives |
Indocin can retain a profitable tail even after broad generic erosion. That tail is usually too small to support a large valuation premium unless the owner controls a scarce dosage form, has an effective distribution agreement, or acquires a broader portfolio around it.
When did Indocin lose market exclusivity?
Indocin lost meaningful market exclusivity decades ago. Indomethacin was introduced in the 1960s, and the original composition-of-matter and product patents expired long before the modern Hatch-Waxman environment reached maturity.
No current U.S. regulatory exclusivity period materially protects the original Indocin product. The relevant commercial protection is therefore not data exclusivity or patent exclusivity. It is residual brand demand and product-specific distribution.
The U.S. Food and Drug Administration’s Orange Book identifies approved drug products, therapeutic-equivalence information, patent listings, and exclusivity information. For an old product such as Indocin, the central issue is whether any listed patent remains unexpired and relevant to an approved formulation or use. [2]
What patents protect Indocin?
No commercially significant unexpired U.S. patent estate is generally associated with the original Indocin capsules as a product. The historic patent estate covered indomethacin and related indole acetic-acid compounds, but those rights expired many years ago.
Patent categories relevant to Indocin
| Patent category |
Current commercial significance |
| Original indomethacin compound patents |
Expired |
| Original capsule formulation patents |
Expired or no longer commercially material |
| Manufacturing patents |
Generally expired, nonblocking, or avoidable |
| Method-of-use patents |
No broad, commercially meaningful exclusivity for the original indications |
| Salt or polymorph patents |
Limited relevance to standard generic indomethacin |
| Reformulation patents |
Relevant only to separate products such as Tivorbex or other delivery systems |
The patent analysis changes when the product is a reformulation. A lower-dose or modified-release product can rely on formulation, dosing, pharmacokinetic, or method-of-use patents even when the active ingredient is old. Those rights protect the specific product, not indomethacin as a molecule.
What is the Orange Book status of Indocin?
Indocin’s Orange Book position is consistent with a mature product:
- The original drug is approved under a legacy new drug application.
- Generic indomethacin products may be approved through abbreviated new drug applications.
- The active ingredient has no meaningful remaining new chemical entity exclusivity.
- Generic substitution is available where the relevant dosage form has an FDA-rated equivalent product.
- Any listed patents must be evaluated by dosage form, strength, and approved indication rather than by the Indocin name alone.
An Orange Book listing does not itself prove that a patent blocks every generic product. The patent must cover the relevant drug, formulation, method of use, or manufacturing process, and a generic applicant may challenge it through a Paragraph IV certification or carve out a patented indication.
Are there Paragraph IV challenges to Indocin?
Paragraph IV litigation is not a major current commercial issue for the original Indocin product. The product’s age and the availability of generic indomethacin indicate that the central patent disputes occurred, if at all, during earlier generic-entry periods.
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. For Indocin, any historic challenge would have addressed an Orange Book-listed patent associated with a particular dosage form or use. Because the core active-ingredient patents expired long ago, a new Paragraph IV dispute would more likely concern a reformulated product than standard Indocin capsules.
No active, high-value Paragraph IV conflict is identified here as a current barrier to generic indomethacin access.
What formulation patents protect indomethacin products?
Formulation protection is more relevant for differentiated indomethacin products than for legacy Indocin.
Conventional capsules
Standard immediate-release capsules have limited patent defensibility. A generic manufacturer can typically use conventional excipients and a different manufacturing process while relying on bioequivalence rather than duplicating every commercial detail of the brand.
Suppositories
Suppositories may have greater operational barriers than capsules because they require:
- Specialized manufacturing equipment.
- Controlled melting and solidification characteristics.
- Stability testing.
- Dose uniformity across a nonoral delivery system.
- Reliable supply of suitable excipients.
These are manufacturing and quality barriers, not necessarily enforceable patent barriers.
Oral suspension
An oral suspension can have more complex formulation requirements, including particle-size control, sedimentation behavior, redispersibility, taste, preservative systems, and dose uniformity. Those characteristics can support formulation patents or regulatory differentiation, but they do not automatically create market exclusivity.
Reformulated indomethacin products
Tivorbex is a separate branded indomethacin product positioned around low-dose immediate-release capsules for acute pain. Its commercial protection has relied more heavily on product-specific regulatory and patent rights than the original Indocin product. [3]
What FDA regulatory status applies to Indocin?
Indocin is an FDA-approved prescription NSAID. The approved labeling covers inflammatory and rheumatic conditions, including:
- Moderate-to-severe rheumatoid arthritis.
- Osteoarthritis.
- Ankylosing spondylitis.
- Acute painful shoulder.
- Acute gouty arthritis.
- Bursitis and tendinitis.
The FDA label includes boxed warnings for cardiovascular thrombotic events and gastrointestinal bleeding, ulceration, and perforation. It also contains warnings relating to renal effects, hypertension, heart failure, hepatic effects, hypersensitivity, and pregnancy. [1]
The regulatory status creates a mixed commercial effect. Broad labeling supports physician awareness, but the safety profile limits long-term use and encourages dose minimization. Indomethacin is often used when its anti-inflammatory potency or specific clinical familiarity is valued, rather than as a default first-line NSAID for every patient.
How does Indocin compare with competing drugs?
| Drug |
Relative commercial strength |
Main competitive advantage |
| Ibuprofen |
Very strong generic and OTC presence |
Low cost, broad consumer familiarity |
| Naproxen |
Strong generic and OTC presence |
Duration of action and perceived cardiovascular profile |
| Diclofenac |
Strong generic presence |
Multiple oral and topical dosage forms |
| Celecoxib |
Branded and generic presence |
COX-2 selectivity and reduced gastrointestinal burden in selected patients |
| Ketorolac |
Generic, acute-use product |
Potent short-term analgesia |
| Indomethacin |
Mature generic and limited brand presence |
Potency, gout use, specialty familiarity |
| Indocin |
Small branded tail |
Brand recognition and selected dosage forms |
Indocin is most defensible in clinical niches where physicians specifically prefer indomethacin or where a dosage form is not readily available from all suppliers. It is less competitive in routine musculoskeletal pain, where cheaper generic NSAIDs and OTC products dominate.
What generic launch risks exist for Indocin?
Generic launch risk is high for any remaining branded Indocin volume because:
- The active ingredient is old and widely known.
- Generic indomethacin is already available.
- Standard capsules have limited technical complexity.
- Prescribers can switch among NSAIDs.
- Payers generally favor generic substitution.
- No broad composition-of-matter patent blocks entry.
The principal risks are commercial rather than legal:
- A generic manufacturer can undercut the brand.
- Pharmacy substitution can remove brand volume without a new prescription.
- Multiple suppliers can reduce scarcity premiums.
- A competitor can match the dosage form and strength.
- Payers can impose higher patient costs for branded Indocin.
Residual brand value is stronger where the product is a scarce suppository or suspension, where a hospital contract requires a specific supplier, or where supply disruptions affect competing products.
Which companies are challenging Indocin commercially?
The competitive field includes manufacturers of generic indomethacin capsules, extended-release products, suppositories, and suspension. Depending on product and market, generic suppliers have included large U.S. and international manufacturers such as Teva, Hikma, Amneal, Rising Pharmaceuticals, and other ANDA holders.
The commercial challenge does not require direct brand-to-brand promotion. Generic substitution, formulary placement, wholesaler stocking, and pharmacy procurement can displace Indocin automatically.
No single competitor needs to capture the entire market. A fragmented generic field can collectively erode the brand’s volume and pricing.
What licensing deals affect Indocin?
No major current licensing transaction is necessary to explain Indocin’s market position. The product’s value is more likely linked to portfolio acquisitions, commercialization rights, or legacy brand transfers than to a strategic co-development partnership.
Licensing economics would be constrained by:
- Low expected growth.
- Generic price competition.
- Limited patent protection.
- Small standalone revenue.
- Manufacturing and supply obligations.
- Regulatory maintenance costs.
A buyer would typically assess Indocin as a cash-flow or portfolio product rather than as a platform asset.
What manufacturing and geographic barriers remain?
The United States is the most important regulatory market for Orange Book and ANDA analysis, but commercial conditions vary by region.
| Region |
Market characteristic |
| United States |
Generic substitution, FDA-approved dosage forms, payer pressure |
| European Union |
National reimbursement and decentralized generic competition |
| Japan |
Local regulatory requirements and prescribing differences |
| Emerging markets |
Greater price sensitivity and variable brand recognition |
Manufacturing barriers are highest for suppositories, suspensions, and sterile or hospital-use indomethacin products. They are lower for conventional capsules. API sourcing, quality-system compliance, validation, and supply continuity can matter more than patents.
How strong is the Indocin patent estate?
The patent estate is weak for the original product and potentially stronger for separately protected reformulations.
| Asset |
Patent strength |
Commercial implication |
| Original Indocin capsules |
Low |
Generic competition established |
| Original Indocin suppositories |
Low to moderate |
Dosage-form scarcity may support residual value |
| Original oral suspension |
Low to moderate |
Technical manufacturing complexity |
| Reformulated branded indomethacin |
Product-dependent |
Patents may protect dosing or formulation |
| Indomethacin API manufacturing |
Low as a blocking strategy |
Alternative processes may be available |
Patent strength should not be confused with product availability. An old drug can have weak patents but retain value if competitors exit, suppliers fail, or a dosage form becomes scarce.
What is the likely generic launch scenario?
The base case is continued generic dominance with a shrinking branded tail.
Base case
Generic indomethacin remains available across common dosage forms. Indocin retains limited prescriptions from brand-loyal physicians, selected patients, and institutions. Net pricing remains under pressure.
Upside case
A supply disruption, generic withdrawal, or shortage temporarily increases demand for the branded product or a niche dosage form. The effect would likely be temporary unless the owner secures durable supply advantages.
Downside case
Additional generic suppliers enter, current suppliers improve availability, and payers tighten substitution rules. Brand volume and pricing decline further.
The highest-value defense is not a new patent on legacy capsules. It is reliable supply, differentiated delivery, a clinically meaningful formulation, or an acquisition strategy that combines Indocin with other specialty products.
Key Takeaways
- Indocin is a mature indomethacin brand with limited standalone financial transparency.
- Core composition and product patent protection expired long ago.
- Generic indomethacin creates the principal competitive pressure.
- No major current Paragraph IV or biosimilar issue affects the product.
- Biosimilar risk is not applicable because Indocin is a small-molecule drug, not a biologic.
- Suppositories and oral suspension may retain niche value through manufacturing complexity and limited supplier participation.
- The FDA safety profile limits chronic-use expansion.
- Financial value is likely concentrated in residual brand prescriptions, niche dosage forms, and portfolio-level cash flow.
- Any investment thesis depends more on supply reliability and portfolio synergies than on patent exclusivity.
FAQs
Is Indocin still under patent protection?
The original Indocin product is not protected by the historic indomethacin compound patents. Any relevant current patent must be assessed separately for a specific formulation, strength, dosage form, or method of use.
Is generic indomethacin therapeutically equivalent to Indocin?
FDA-rated generic products may be therapeutically equivalent to the corresponding reference-listed drug when the dosage form, strength, route, and regulatory rating match. Product-specific substitution should be evaluated through the current Orange Book. [2]
Does Indocin have biosimilar competition?
No. Indocin contains indomethacin, a small-molecule active ingredient. Competition proceeds through generic-drug pathways, not the biosimilar pathway.
Why can an old NSAID remain commercially available?
An old drug can remain viable through persistent clinical demand, low development costs, niche dosage forms, brand recognition, and institutional purchasing. Availability does not imply meaningful patent exclusivity.
Is Indocin more commercially valuable than generic indomethacin?
The brand may command higher net pricing in selected channels, but generic indomethacin has broader volume potential. The relative value depends on brand retention, dosage-form scarcity, supply reliability, and payer substitution policies.
References
-
U.S. Food and Drug Administration. (2023). Indocin (indomethacin) capsules, suppositories, and oral suspension prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
-
U.S. Food and Drug Administration. (2024). Tivorbex (indomethacin) capsules prescribing information. DailyMed.
